GEAP202616911A - Anti-cd30l antibodies and uses thereof - Google Patents

Anti-cd30l antibodies and uses thereof

Info

Publication number
GEAP202616911A
GEAP202616911A GEAP202616911A GEAP2026016911A GEAP202616911A GE AP202616911 A GEAP202616911 A GE AP202616911A GE AP202616911 A GEAP202616911 A GE AP202616911A GE AP2026016911 A GEAP2026016911 A GE AP2026016911A GE AP202616911 A GEAP202616911 A GE AP202616911A
Authority
GE
Georgia
Prior art keywords
cd30l antibodies
cd30l
antibodies
disease
ibd
Prior art date
Application number
GEAP202616911A
Other languages
English (en)
Georgian (ka)
Inventor
Jessie-Farah Fecteau
Mark Renshaw
Johan Fransson
Olivier Laurent
Burton Barnett
Original Assignee
Dr Falk Pharma Gmbh
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Falk Pharma Gmbh, Prometheus Biosciences Inc filed Critical Dr Falk Pharma Gmbh
Publication of GEAP202616911A publication Critical patent/GEAP202616911A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GEAP202616911A 2021-02-17 2022-02-16 Anti-cd30l antibodies and uses thereof GEAP202616911A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163150373P 2021-02-17 2021-02-17

Publications (1)

Publication Number Publication Date
GEAP202616911A true GEAP202616911A (en) 2026-04-27

Family

ID=82931610

Family Applications (4)

Application Number Title Priority Date Filing Date
GEAP202616911A GEAP202616911A (en) 2021-02-17 2022-02-16 Anti-cd30l antibodies and uses thereof
GEAP202216351A GEP20257791B (en) 2021-02-17 2022-02-16 Anti-cd30l antibodies and uses thereof
GEAP202416351A GEAP202416351A (en) 2021-02-17 2022-02-16 Anti-cd30l antibodies and uses thereof
GEAP202516710A GEAP202516710A (en) 2021-02-17 2022-02-16 Anti-cd30l antibodies and uses thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
GEAP202216351A GEP20257791B (en) 2021-02-17 2022-02-16 Anti-cd30l antibodies and uses thereof
GEAP202416351A GEAP202416351A (en) 2021-02-17 2022-02-16 Anti-cd30l antibodies and uses thereof
GEAP202516710A GEAP202516710A (en) 2021-02-17 2022-02-16 Anti-cd30l antibodies and uses thereof

Country Status (20)

Country Link
US (4) US20240254246A1 (enExample)
EP (1) EP4294840A4 (enExample)
JP (2) JP7559257B2 (enExample)
KR (1) KR20230157356A (enExample)
CN (2) CN117255802A (enExample)
AR (1) AR124895A1 (enExample)
AU (1) AU2022224561A1 (enExample)
BR (1) BR112023016445A2 (enExample)
CA (1) CA3208060A1 (enExample)
CL (2) CL2023002393A1 (enExample)
CO (1) CO2023011962A2 (enExample)
CR (1) CR20230445A (enExample)
EC (1) ECSP23070234A (enExample)
GE (4) GEAP202616911A (enExample)
IL (1) IL305146A (enExample)
JO (1) JOP20230186A1 (enExample)
MX (1) MX2023009621A (enExample)
PE (1) PE20231680A1 (enExample)
TW (1) TW202302637A (enExample)
WO (1) WO2022177963A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4081241A4 (en) 2019-12-24 2024-05-01 Juvena Therapeutics, Inc. REGENERATIVE POLYPEPTIDES AND USES THEREOF
PE20231680A1 (es) * 2021-02-17 2023-10-19 Dr Falk Pharma Gmbh Anticuerpos anti-cd30l y usos de estos
EP4359425B1 (en) 2021-06-21 2026-08-05 Juvena Therapeutics, Inc. Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury
AU2023315888A1 (en) * 2022-07-25 2025-02-06 Prometheus Biosciences, Inc. Anti-cd30l antibodies, formulations therefor, and uses thereof
WO2024143497A1 (ja) * 2022-12-28 2024-07-04 国立大学法人京都大学 Ｃｄ１５３を標的とする医薬組成物
KR20260074680A (ko) * 2023-09-12 2026-05-26 암젠 인크 항-cd30l 항체 및 이의 용도
CN122055382A (zh) * 2023-10-03 2026-05-15 国立大学法人京都大学 靶向人cd153的抗体和嵌合抗原受体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ATE311895T1 (de) * 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1667730T3 (da) 2003-08-20 2013-09-23 Univ Miami Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom
WO2013059732A1 (en) * 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
CN104507968B (zh) * 2012-04-27 2019-02-05 诺和诺德股份有限公司 人cd30配体抗原结合蛋白
EP2945865B1 (en) 2013-01-18 2019-01-09 LORD Corporation Active vibration control devices, systems, and methods
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
WO2017127537A1 (en) 2016-01-19 2017-07-27 Thomas Blumenthal Down syndrome biomarkers and uses thereof
PT3774897T (pt) * 2018-04-30 2023-11-10 Cedars Sinai Medical Center Métodos e sistemas para seleção e tratamento de pacientes com doenças inflamatórias
WO2020096046A1 (ja) 2018-11-09 2020-05-14 国立大学法人大阪大学 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン
PE20231680A1 (es) * 2021-02-17 2023-10-19 Dr Falk Pharma Gmbh Anticuerpos anti-cd30l y usos de estos

Also Published As

Publication number Publication date
PE20231680A1 (es) 2023-10-19
CL2023002393A1 (es) 2024-03-22
CA3208060A1 (en) 2022-08-25
JOP20230186A1 (ar) 2023-08-09
ECSP23070234A (es) 2023-10-31
JP2024509746A (ja) 2024-03-05
CN118047872A (zh) 2024-05-17
EP4294840A4 (en) 2025-06-11
EP4294840A1 (en) 2023-12-27
BR112023016445A2 (pt) 2023-12-12
US20230060624A1 (en) 2023-03-02
US12516126B2 (en) 2026-01-06
CR20230445A (es) 2023-11-14
GEP20257791B (en) 2025-09-10
CN117255802A (zh) 2023-12-19
GEAP202516710A (en) 2025-05-13
KR20230157356A (ko) 2023-11-16
WO2022177963A1 (en) 2022-08-25
IL305146A (en) 2023-10-01
MX2023009621A (es) 2023-10-31
CO2023011962A2 (es) 2023-09-29
US11866505B2 (en) 2024-01-09
TW202302637A (zh) 2023-01-16
US20260209372A1 (en) 2026-07-23
JP7559257B2 (ja) 2024-10-01
JP2025004013A (ja) 2025-01-14
US20240254246A1 (en) 2024-08-01
AU2022224561A9 (en) 2023-10-05
US20240092923A1 (en) 2024-03-21
AU2022224561A1 (en) 2023-09-28
GEAP202416351A (en) 2024-02-12
CL2026000881A1 (es) 2026-06-12
AR124895A1 (es) 2023-05-17

Similar Documents

Publication Publication Date Title
GEAP202516710A (en) Anti-cd30l antibodies and uses thereof
ZA202204557B (en) Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
MY191324A (en) Neutralizing anti-tl1a monoclonal antibodies
MA58170B1 (fr) Dérivés carboxy avec des proprietes anti-inflammatoires
WO2019209995A3 (en) Optimized anti-tl1a antibodies
EP3414573A4 (en) NOVEL ANTI-LAM AND ANTI-PIM6 / LAM MONOCLONAL ANTIBODIES FOR THE DIAGNOSIS AND TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTIONS
JOP20230185A1 (ar) تركيبات تشتمل على أجسام مضادة متوافقة مع البشر لمركب ترابطي 1a شبيه بـ tnf (tl1a) واستخداماتها
JOP20210030A1 (ar) مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
EA201892790A1 (ru) Применение 2-замещенных индазолов для лечения и профилактики аутоиммунных заболеваний
EP4296285A3 (en) Methods and systems for selection and treatment of patients with inflammatory diseases
EP3762015A4 (en) METHOD OF TREATMENT OF CROHN'S DISEASE WITH ANTI-IL23 SPECIFIC ANTIBODY
EP3502248A4 (en) ANTIBODIES AGAINST HMGB1 AND COMPOSITION THERE FOR TREATING OR PREVENTING MORBUS ALZHEIMER
MX2022008842A (es) Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.
MX2025001038A (es) Anticuerpos anti-cd30l, formulaciones de estos, y uso de los mismos
EP3603647A4 (en) PHARMACEUTICAL COMPOSITION WITH ADENOSINE DERIVATIVE FOR THE PREVENTION AND TREATMENT OF GLAUCOMA
FR3070263B1 (fr) Composition pour son utilisation dans le traitement et/ou la prevention de l’infertilite
DOP2023000160A (es) Anticuerpos anti-cd30l y usos de estos
NZ787680A (en) Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
EA200900602A1 (ru) Применение альфа 1-тимозина для приготовления лекарства для профилактики и лечения аутоиммунных заболеваний
MA46437B1 (fr) Agonistes de ppar, composés, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci.
EA202191724A1 (ru) Ингибиторы пути jak1 для лечения заболевания желудочно-кишечного тракта
EA202092133A1 (ru) Применение антител против il-36r для лечения воспалительного заболевания кишечника
WO2017064564A3 (en) Therapeutic regimens for treating psoriatic arthritis with an anti-ccl20 antibody
FR3050380B1 (fr) Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains.